Skip to main content
Premium Trial:

Request an Annual Quote

Second Genome Inks Development Deal with Janssen; Raises Additional $6.5M

NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.

Second Genome also announced it raised an additional $6.5 million in Series A financing.

Its deal with Janssen is focused on "therapeutic mechanisms in ulcerative colitis mediated by" the microbiome. As part of the deal, the San Bruno, Calif.-based firm will use its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis. The firm's proprietary method for generating therapeutic candidates modulates microbe-microbe and microbe-human interactions that influence health and disease, it said.

According to Peter DiLaura, president and CEO of Second Genome, "This collaboration with Janssen will identify mechanisms by which microbial populations in the gut have an impact in ulcerative colitis."

In connection with the agreement, Second Genome will receive an upfront payment and is eligible for potential payments contingent on certain research milestones being achieved. Janssen will also provide support for research activities jointly performed in collaboration with Second Genome.

The Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development will fund the research, Second Genome said.

The company also announced it raised an additional $6.5 million in Series A financing, bringing the total raised in the round to $11.5 million.

The funding will go toward accelerating programs in metabolic disease, inflammation, and infection.

Current investors participated in the latest raise, including Advanced Technology Ventures, Morgenthaler, and Wavepoint Ventures. Individuals, such as company Co-Founder and Chairman Corey Goodman, and board member Matt Winkler, also participated.

Additionally, the company said that former CEO and Co-founder of Envoy Therapeutics Brad Margus has joined Second Genome's board. University of California, San Diego Professor of Medicine Jerrold Olefsky was appointed to the company's scientific advisory board.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.